Therapies
Follow a treatment from its biology to its evidence. Search generic names, trade names and development codes.
67 therapies
ABBV-295
A long-acting amylin analogue that activates both amylin and calcitonin receptors.
GUB014295Weight & glucoseAleniglipron
An oral small molecule that activates GLP-1 receptors.
GSBR-1290Lipids & cardiovascular healthAlirocumab
Binds circulating PCSK9 and prevents PCSK9-mediated loss of LDL receptors.
PraluentMuscle preservationApitegromab
Explore the study evidence, development history and source references.
Isembyld · apitegromab-mstn · SRK-015Weight & glucoseASC30
A small molecule that activates GLP-1 receptors; the sponsor describes its receptor signaling as fully biased.
Evidence, biology & developmentLipids & cardiovascular healthAtorvastatin
Inhibits HMG-CoA reductase, an enzyme in cholesterol synthesis.
LipitorWeight & glucoseBeinaglutide
Activates GLP-1 receptors. Its amino-acid sequence matches human GLP-1 (7–36).
Feisumei (菲塑美) · Yishengtai (谊生泰) · BenaglutideLipids & cardiovascular healthBempedoic acid
After activation to a CoA derivative, inhibits ATP-citrate lyase in the liver, reducing cholesterol synthesis.
Nexletol · Nexletol / NilemdoLipids & cardiovascular healthBempedoic acid + ezetimibe
Combines ATP-citrate lyase inhibition by activated bempedoic acid with intestinal NPC1L1 inhibition by ezetimibe.
NexlizetWeight & glucoseBerobenatide
A long-acting peptide that activates GLP-1 receptors; weekly and monthly dosing are being studied.
PF-08653944 · PF’3944 · MET-097i · MET097Weight & glucoseBGM0504
Activates both GLP-1 and GIP receptors.
Evidence, biology & developmentMuscle preservationBimagrumab
Explore the study evidence, development history and source references.
Evidence, biology & developmentWeight & glucoseBofanglutide
A long-acting peptide that activates GLP-1 receptors.
GZR18Weight & glucoseCagrilintide
An amylin analogue that activates amylin receptors and also activates calcitonin receptors.
AM833Weight & glucoseCagriSema
Combines semaglutide’s GLP-1 activity with cagrilintide’s amylin and calcitonin receptor activity.
Cagrilintide + semaglutideResearch programCBL-514
Published abdominal-fat results, pivotal trials and exploratory combination research.
Evidence, biology & developmentResearch programClascoterone 5%
Male pattern hair loss: pivotal scalp-trial results and planned U.S. and European filings.
ClascoteroneResearch programCOMP360
Psilocybin for treatment-resistant depression: trials and the U.S. application.
PsilocybinWeight & glucoseConveglipron
An oral small molecule that activates GLP-1 receptors.
HDM1002Weight & glucoseCT-996
An oral small molecule that activates GLP-1 receptors.
Evidence, biology & developmentWeight & glucoseEcnoglutide
Activates GLP-1 receptors, favoring cAMP signaling while reducing recruitment of beta-arrestin. Oral and injectable formulations contain the same receptor-active compound.
Xianweiying (先维盈) · Xianyida (先颐达) · XW003 · XW004Weight & glucoseEfsubaglutide alfa
A long-acting protein medicine that activates GLP-1 receptors.
Diabegone (怡诺轻) · Suba · YN011 · SupaglutideWeight & glucoseElecoglipron
An oral small molecule that activates GLP-1 receptors.
AZD5004 · ECC5004Weight & glucoseEloralintide
Preferentially activates amylin receptors. Laboratory studies also found weaker calcitonin receptor activity; the targets do not have equal potency, and their separate contributions to weight loss are not established.
LY3841136Weight & glucoseEloraTZP
Eloralintide activates amylin receptors; tirzepatide activates GLP-1 and GIP receptors. The phase 2b study used separate injections. A co-formulated product is planned for phase 3; minimal calcitonin-receptor activity is not presented as an equal therapeutic target.
Eloralintide + tirzepatideWeight & glucoseEnicepatide
Activates GLP-1 and GIP receptors with signaling biased toward cAMP.
CT-388 · RO7795068Lipids & cardiovascular healthEnlicitide
Binds PCSK9 and inhibits its interaction with the LDL receptor.
LipfendraLipids & cardiovascular healthEvinacumab
Binds and inhibits ANGPTL3, relieving its inhibition of lipoprotein lipase and endothelial lipase.
EvkeezaLipids & cardiovascular healthEvolocumab
Prevents PCSK9 from binding LDL receptors, increasing the receptors available to clear LDL.
RepathaLipids & cardiovascular healthEzetimibe
Blocks the intestinal sterol transporter NPC1L1, reducing cholesterol absorption.
ZetiaLipids & cardiovascular healthEzetimibe + simvastatin
Combines intestinal cholesterol-absorption inhibition by ezetimibe with HMG-CoA reductase inhibition by activated simvastatin.
Vytorin · ezetimibe also sold as ZetiaWeight & glucoseHRS-4729 (KAI-4729)
Activates GLP-1, GIP and glucagon receptors.
KAI-4729Weight & glucoseHRS-7535 (KAI-7535)
An oral small molecule that activates GLP-1 receptors.
KAI-7535Lipids & cardiovascular healthIcosapent ethyl
Provides EPA after de-esterification. Proposed triglyceride effects include reduced liver VLDL-triglyceride production and increased clearance; the mechanisms of cardiovascular-event reduction are not fully understood.
Vascepa / VazkepaLipids & cardiovascular healthInclisiran
Uses RNA interference to break down PCSK9 messenger RNA in liver cells, reducing PCSK9 production.
LeqvioResearch programLecanemab (Leqembi)
Early Alzheimer’s treatment: clinical benefit, safety monitoring, home dosing and prevention research.
Lecanemab · LeqembiLipids & cardiovascular healthLepodisiran
Targets the messenger RNA for apolipoprotein(a), reducing its production in liver cells.
Evidence, biology & developmentWeight & glucoseLiraglutide
Mimics GLP-1 activity by activating its receptors, reducing calorie intake.
Saxenda · VictozaWeight & glucoseMaridebart cafraglutide (MariTide)
Activates GLP-1 receptors and blocks GIP receptors through a peptide–antibody conjugate.
Maridebart cafraglutide · AMG 133Weight & glucoseMazdutide
Activates both GLP-1 and glucagon receptors.
Xinermei (信尔美) · IBI362 · LY3305677Lipids & cardiovascular healthMuvalaplin
Disrupts the interaction between apolipoprotein(a) and apoB-100, inhibiting lipoprotein(a) assembly.
Evidence, biology & developmentLipids & cardiovascular healthObicetrapib
Inhibits cholesteryl ester transfer protein (CETP).
Ubeslo · EvlarcoLipids & cardiovascular healthOlezarsen
Targets apoC-III messenger RNA to reduce apoC-III protein production.
TryngolzaLipids & cardiovascular healthOlpasiran
Suppresses apolipoprotein(a) production by targeting LPA messenger RNA in liver cells.
Evidence, biology & developmentLipids & cardiovascular healthOmega-3 carboxylic acids (EPA + DHA)
The triglyceride-lowering mechanism is not fully understood; proposed effects include reduced liver triglyceride synthesis and increased fatty-acid oxidation and lipoprotein-lipase activity.
Epanova (studied formulation)Weight & glucoseOrforglipron
An oral small molecule that activates the human GLP-1 receptor.
Foundayo · LY3502970Lipids & cardiovascular healthPelacarsen
Targets apolipoprotein(a) messenger RNA, reducing apolipoprotein(a) production.
Evidence, biology & developmentLipids & cardiovascular healthPemafibrate
Selectively modulates peroxisome proliferator-activated receptor alpha (PPAR-alpha).
Parmodia (Japan)Weight & glucosePemvidutide
Activates GLP-1 and glucagon receptors.
ALT-801Weight & glucosePetrelintide
A long-acting human amylin analogue with balanced activation of amylin and calcitonin receptors.
ZP8396Lipids & cardiovascular healthPlozasiran
Uses RNA interference to degrade apoC-III messenger RNA, reducing apoC-III protein production.
RedemploWeight & glucosePoterepatide
Activates both GLP-1 and GIP receptors.
HDM1005Weight & glucoseRAY1225
Activates both GLP-1 and GIP receptors; the sponsor describes it as a biased receptor agonist.
Evidence, biology & developmentWeight & glucoseRetatrutide
One molecule activates GLP-1, GIP and glucagon receptors.
LY3437943Weight & glucoseRibupatide
Activates both GLP-1 and GIP receptors. The injectable and oral formulations share these targets.
HRS9531 tablet · KAI-9531-T · HRS9531 · KAI-9531Lipids & cardiovascular healthRosuvastatin
Inhibits HMG-CoA reductase, an enzyme in cholesterol synthesis.
CrestorWeight & glucoseSemaglutide
Activates GLP-1 receptors. Oral and injected semaglutide have the same receptor target; formulation and dose differ.
Wegovy (injection) · Wegovy HD · Wegovy (pill) · Ozempic (injection)Lipids & cardiovascular healthSimvastatin
After conversion to its active hydroxy-acid form, inhibits HMG-CoA reductase in cholesterol synthesis.
ZocorLipids & cardiovascular healthSolbinsiran
Uses RNA interference directed at ANGPTL3 messenger RNA to reduce ANGPTL3 production in the liver.
Evidence, biology & developmentWeight & glucoseSurvodutide
Activates GLP-1 and glucagon receptors.
BI 456906Weight & glucoseTG103 (efmedaglutide alfa)
Activates GLP-1 receptors. The GLP-1 component is joined to an Fc protein to prolong its action.
GLP-1/Fc fusion protein · TJ103 · Efmedaglutide alfaWeight & glucoseTirzepatide
One molecule mimics GLP-1 and GIP by activating both hormones’ receptors.
Zepbound · MounjaroWeight & glucoseUBT251
Activates GLP-1, GIP and glucagon receptors.
Evidence, biology & developmentLipids & cardiovascular healthVERVE-102
Designed to edit the PCSK9 gene in liver cells, reducing PCSK9 production.
Evidence, biology & developmentWeight & glucoseVK2735
Activates both GLP-1 and GIP receptors; the same compound is being studied as an injection and an oral tablet.
VK2735 tabletWeight & glucoseZenagamtide
Also called amycretin. One peptide activates GLP-1, amylin and calcitonin receptors. Oral and injected forms share these targets.
Amycretin · NNC0487-0111 · NN9487Lipids & cardiovascular healthZodasiran
Targets ANGPTL3 messenger RNA to reduce hepatic ANGPTL3 protein production.
Evidence, biology & development